Financial & Valuation Intelligence™
Rossari Biotech Limited
NSE
ROSSARI
Sector: Chemicals· Specialty ChemicalsCurrent Price
₹411.9
Market Cap
₹2.52K Cr
AI Financial Summary
Rossari Biotech Limited displays robust top-line momentum with a 24.52% revenue CAGR, though profitability metrics have faced compression as the business has scaled. While the company maintains a solid balance sheet and favorable valuation, long-term shareholder value creation depends on stabilizing margins and improving free cash flow generation.
Business Performance (CAGR)
10 Years
Revenue
24.5%
PAT
18.4%
EPS
16.2%
Book Value
37.7%
Free Cash Flow
6202.6%
Valuation Snapshot
P/E14.1
P/B1.6
EV/EBITDA10
P/S1.1
Div Yield0.11%
Financial Health
Debt to Equity0.33
Interest Coverage8.1x
Current Ratio2.09
Cash & Investments₹155 Cr
Profitability Metrics
ROE
11.2%
ROCE
13.1%
ROA
6.6%
EBITDA Mgn
11.9%
Op Margin
9.6%
Net Margin
6.2%
Cash Flow Intelligence
Operating Cash Flow₹65 Cr
Free Cash Flow₹-233 Cr
Cash Conversion43.6%
FCF Margin-9.7%
Intrinsic Value
PremiumEstimated Intrinsic Value
████████
Current Price₹411.9
Margin of Safety██.██%
Estimated Intrinsic Value & DCF Fair Value are available with Premium plans.
AI Business Verdict
Rossari Biotech shows potential as a growth-oriented firm with a strong balance sheet and attractive valuation, though investors should monitor the volatility in cash flow and margin trends closely.
- Strong historical revenue growth trajectory
- Conservative leverage and healthy interest coverage
- Significant margin of safety based on current intrinsic value estimates
- Scalable business model within the specialty chemicals industry
Balance Sheet
AI-Powered Analysis
Balance Sheet Strength™
71/100
Good
Rossari Biotech Limited maintains a balanced sheet with adequate liquidity and manageable leverage.
AI Confidence
92%
Stability
66
Flexibility
69
Strength Factors
Liquidity84
Leverage86
Working Capital52
Asset Quality40
Shareholder Strength100
Financial Stability66
Financial Flexibility™
69/100
Good
Capacity to fund growth, withstand downturns and return capital.
Total Assets
₹2.27K Cr
▲ 37.3% YoY
Total Liabilities
₹941 Cr
▲ 100.0% YoY
Shareholder Equity
₹1.33K Cr
▲ 12.5% YoY
Net Cash Position
₹-281 Cr
Monitor
Debt / Equity
0.33x
Manageable
Enterprise Value
₹2.80K Cr
Capital Structure
Assets
₹2.27K Cr
Equity
₹1.33K Cr (58.6%)
Liabilities
₹941 Cr (41.4%)
Debt Intelligence™
Debt vs Cash Trend
Debt / Equity0.33x
Interest Coverage8.1x
Debt / EBITDA2.92x
Net Debt₹281 Cr
Debt Trend (5Y)125.1%
Debt MaturityWell Staggered
Liquidity Intelligence™
Current Ratio2.09
Quick Ratio1.29
Cash Ratio0.10
Working Capital₹550 Cr
Operating Cash CoverageGood
Short-term LiquidityStrong
Working Capital Intelligence™
CCC Trend
Receivable Days85
Inventory Days62
Payable DaysNot Available
Cash Conversion Cycle147 days
Asset Quality (% of Total Assets)
Cash & Investments4.1%
Property, Plant & Equip.34.5%
ReceivablesNot Available
InventoryNot Available
GoodwillNot Available
Intangible AssetsNot Available
Other Assets57.9%
Shareholder Strength™
Strength Radar
Book Value CAGR (5Y)37.7%
Net Worth CAGR (5Y)40.4%
Retained EarningsExcellent
Equity Dilution0.00%
Buyback EfficiencyGood
Dividend Sustain.Strong
Balance Sheet Evolution
Annual
Balance Sheet Risk Monitor
Debt RiskLow
Liquidity RiskLow
Working Capital RiskElevated
Refinancing RiskLow
Asset Quality RiskHigh
Dilution RiskLow
Contingent LiabilityLow
Overall Balance Sheet RiskModerate
Balance Sheet Stress Test™
Economic Slowdown52
Acquisition Capacity74
High Interest Rates90
Dividend Sustainability85
Revenue Decline77
Cash Flow Resilience68
Expansion Capacity81
Overall Resilience Score
75/100
Strong Resilience
AI Balance Sheet Commentary
Overall Assessment
- Rossari Biotech Limited maintains a balanced sheet with adequate liquidity and manageable leverage.
What Stands Out
- Strong shareholder equity growth
- Comfortable short-term liquidity cushion
Areas To Monitor
- Long working capital cycle
- Large 'other assets' bucket — investigate composition
Financial data based on consolidated numbers and TTM · Source: Company Filings, Annual Report AI Analysis · Data as of: 31/03/2026